Trial results

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT06649045 on ClinicalTrials.gov · last registry update 2025-09-29

Closed to new participants; the 600 already enrolled are still being followed. Due to report November 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Apnea-Hypopnea Index (AHI). Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

600

Started

2024-10-22

Primary completion

2026-11 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in Apnea-Hypopnea Index (AHI)

Conditions studied

OSA · Overweight or Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.